INTRODUCTION
Activating EGFR mutations dictate responsiveness of NSCLCs to reversible 3 EGFR tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib (1) (2) (3) (4) . Despite 4 promising initial responses, acquired resistance universally develops, mediated by the 5 emergence of the secondary T790M mutation or by focal amplification of MET, in 6 approximately 60% and 5% of patients, respectively (5-10). 7 NSCLCs with acquired EGFR TKI resistance that present with an epithelial-to-8 mesenchymal transition (EMT) phenotype have been identified in recent clinical studies 9 (9, (11) (12) (13) . Similarly, NSCLC cells with EGFR TKI sensitizing mutations may develop an 10 EMT phenotype upon chronic exposure to erlotinib (14) (15) (16) . EMT is a cellular program 11 observed in normal development, and is implicated in tumor progression and metastasis 12 (17). Overexpression of the receptor tyrosine kinase AXL has been associated with the 13 EMT gene signature in NSCLC, and confers acquired erlotinib resistance in cell line 14 models (15, 16) . AXL has therefore been proposed as a therapeutic target in EGFR 15 TKI-resistant NSCLC cell lines with EMT phenotype. However, in other studies, AXL 16 inhibition has not sensitized resistant cells with EMT phenotype to EGFR TKIs (18). 17 These conflicting results suggest that developing targeted therapies for NSCLCs that 18 have acquired EGFR TKI resistance via EMT could potentially be difficult, and that a 19 more complete understanding of the mechanisms by which the inhibition of mutant 20 EGFR in NSCLC cells promotes EMT is required. 21 The study of resistance to EGFR TKIs in EGFR-mutated NSCLC is complex, (19, 20) . In this regard, it is important to pre-clinically investigate if EGFR-mutated 4 NSCLC can remain sensitive to EGFR TKIs by successfully suppressing EMT, or 5 whether the acquisition of divergent resistance mechanisms will limit the utility of this 6 strategy. 7 To elucidate the mechanisms promoting EMT in NSCLCs harboring mutated-8 EGFR, we have performed analyses using multiplex growth factor and cytokine assays 9 and genomic signatures of NSCLC cells in which acquired EGFR TKI resistance is 10 associated with the EMT phenotype. We have also evaluated the ability of combined 11 EGFR inhibition and EMT suppression to prevent acquired resistance and have 12 investigated the significance of tumor heterogeneity in NSCLC in the emergence of 13 EGFR TKI acquired resistance. 3 HCC827, HCC4006 and NCI-H1975 NSCLC cells were obtained from the 4 American Type Culture Collection (ATCC) and were maintained as specified. The cell 5 lines were tested by certified third party laboratories for authenticity (Fig.5B and 6 Supplementary Materials and Methods). Details for the STR assay are described in the 7 Supplementary Methods. Genomic DNA from PC9 was used extensively in previous 8 studies and its authenticity has been confirmed (21, 22 ). 
NSCLC Cell lines and STR assays

Generation of EGFR TKI or gefitinib/SB431542 resistant cells
11
In order to generate cell lines resistant to first-generation EGFR TKIs, HCC4006 12 or HCC827 cells were exposed to increasing concentrations of gefitinib or erlotinib over 13 six months in a manner similar to previously described (22-24); however, resulting 14 resistant cell lines for HCC4006 cells are polyclonal and not clones. 15 Gefitinib/SB431542-resistant HCC4006 cells were developed in a similar manner, with 16 continuous exposure to 1 µmol/L SB431542. For HCC827 erlotinib-resistant cells, 17 clones were isolated. All resistant cells are able to proliferate normally in the presence 18 of 10µmol/L gefitinib. Cell viability was used to confirm gefitinib resistance after allowing 19 the cells to grow gefitinib-free for seven days. Upon confirming resistance, cells were 20 cultured without drugs and their resistance to gefitinib was examined periodically. 21 
22
Generation of EGFR TKI resistant cells by TGFβ1 exposure
DNA sequencing
12
EGFR exons 19 and 20 were amplified from DNA from cell lines using primers 13 described previously (27). Resulting PCR products were purified and subjected to 14 Sanger sequencing (Genewiz). Primer sequences and conditions are available in the 15 Supplementary Methods. 16 
17
Detection of EGFR T790M with ddPCR
18
Droplet Digital PCR (ddPCR) was performed at the Belfer Institute, Dana-Farber 19 Cancer Institute, as previously described (28) . 20 
21
Analysis of Microarray Gene Expression Data
22
Gene expression profiling methods are available in the Supplementary Methods. Detection of apoptosis by flow cytometry 1 Adherent cells were removed from plates using Accutase (Life) and pooled. 2 Apoptosis was assessed using an Annexin V-FLUOS Staining Kit (Roche) according to 3 the manufacturer's instructions. 4 5 Murine drug treatment studies 6 Human EGFR exon 19 deletion-T790M (TD)-inducible bitransgenic mice were 7 generated and have been previously characterized (24). After continuous exposure to 8 doxycycline diets for more than 8 weeks, bitransgenic mice were subjected to MRI to Histology and immunohistochemistry 14 After sacrifice, the left lung of each mouse was dissected and snap-frozen for 15 biochemical analysis. The right lung was inflated with buffered 10% formalin for 10min 16 and fixed in 10% formalin overnight at room temperature. 
RESULTS
1
Chronic exposure of EGFR-mutated NSCLC cells to increasing concentrations of 2 gefitinib promotes acquired EGFR TKI resistance with a mesenchymal phenotype. 3 We first generated a mass culture of HCC4006 cells that were resistant to 4 gefitinib (HCC4006Ge-R) by growing cells in increasing concentrations of gefitinib to a 5 final concentration of 10µM for up to 6 months in vitro (Fig.1A) . Cell viability and 6 Annexin V apoptosis assays confirmed that HCC4006Ge-R cells (Ge-R) are highly 7 resistant to gefitinib and afatinib compared to the parental HCC4006 cells (Fig.1B,   8 Suppl. Fig.1A ). Receptor tyrosine kinase (RTK) profiling revealed that EGFR, MET, 9 HER2, and HER3 are tyrosine-phosphorylated in Ge-R cells cultured without gefitinib.
10
Prolonged exposure of Ge-R cells to gefitinib suppressed RTK phosphorylation, except 11 for residual phosphorylation of EGFR and AXL (Fig.1C) . However, the treatment of Ge-
12
R cells with the combination of gefitinib and the AXL inhibitor R428 failed to decrease 13 the viability of Ge-R cells (Suppl. Fig.1B ). The levels of EGFR and MET expression are 14 comparable in HCC4006 and Ge-R cells (Fig.1D) . The morphology of Ge-R cells is 15 characteristic of that observed in mesenchymal cells. Western blot using antibodies 16 against canonical epithelial and mesenchymal markers revealed that Ge-R cells 17 underwent EMT (Fig.1E) . Similarly, NCI-H1975 (H1975) cells harboring L858R/T790M 18 grown resistant to the irreversible EGFR TKI, CL-387,785 (Suppl. Fig.1C ) also 19 demonstrated a mesenchymal phenotype (Suppl. Fig.1D ). 20 In contrast, chronic EGFR inhibition in HCC827 cells predominantly resulted in evidence of MET amplification (Fig.1F) . The mesenchymal clone (ERC4) was resistant 1 to combined EGFR and MET inhibition (Fig.1G) . Gene set enrichment analysis (GSEA) 2 demonstrated that ERC4 cells are mesenchymal with significant gene set enrichment 3 for a gefitinib resistance signature (Suppl. Fig.1E ). 4 In summary, the mass culture of HCC4006 or H1975 cells grown resistant to 5 reversible and irreversible EGFR TKIs, respectively, were mesenchymal, whereas 6 subcloning was necessary to isolate erlotinib-resistant HCC827 cells that are 7 mesenchymal. These experiments demonstrate that the probability of EMT emerging as TGFβ1 promotes EMT and EGFR TKI resistance that are reversible.
Using Luminex-based multiplex assays, we profiled growth factors and cytokines 13 in the supernatants from erlotinib-resistant HCC827 cell clones ( Fig.2A) . In the the cell culture media for more than 30 days partially restored an epithelial phenotype 1 ( Fig.2C ). HCC827 cells were resistant to EGFR TKIs in the TGFβ1-induced 2 mesenchymal state, and the removal of TGFβ1 restored sensitivity (Fig.2D ).
3 Surprisingly, TGFβ1-mediated mesenchymal transition was associated with a significant 4 reduction in ERBB family receptor expression (Fig.2E ) even though the cells were able 5 to proliferate normally. Similarly, exposure of HCC4006 cells to TGFβ1 also promoted 6 mesenchymal transition and EGFR TKI resistance, which was reversible upon removal 7 of TGFβ1 from the media (Supple. Fig.2A ). To extend our findings to in vivo, we assessed if similar events occurred in 20 mouse lung cancers driven by human EGFR exon19 deletion/T790M (TD) that respond 21 to the EGFR mutant-specific irreversible TKI WZ4002 to promote tumor regression (24). Treatment of the mouse tumors with WZ4002 for two days suppressed EGFR activity 1 and activated SMAD2/3 activities, recapitulating our finding in cell lines (Fig.3C) . 2 To eliminate the possibility that off-target effects of erlotinib are responsible for 3 the induction of TGFβ1 secretion we used target-specific short-hairpin RNA (shRNA) - 4 mediated depletion of EGFR in HCC827 cells. Upon puromycin selection, clones with 5 MET overexpression or EMT were isolated (Suppl. Fig.3E ) similar to clones isolated in 6 the erlotinib-resistant population (Fig.1F) . Slight MET amplification was observed in 7 clone 10 but not in clone 9 (Suppl. Fig.3F ). Clone 9 was resistant to gefitinib ( (Fig.3G, p=0 .0011) albeit after prolonged EGFR knockdown. 
Concurrent EGFR and TGFβR inhibition prevents mesenchymal transition but
14
does not avert emergence of EGFR TKI resistance. 15 We next investigated whether co-treatment with an EGFR inhibitor and a TGFβ GeSB-R cells harbor T790M mutation and remain modestly sensitive to AZD9291.
13
At the end of 6 months treatment, HCC4006 cells proliferate normally in the 14 presence of 10µmol/L gefitinib (Ge-R) with a mesenchymal phenotype or in the 15 presence of 10µmol/L gefitinib and 1 µmol/L SB431542 (GeSB-R) with an epithelial 16 phenotype (Suppl. Fig.4B ). Since gefitinib failed to inhibit EGFR in GeSB-R, we 17 challenged the resulting cells with the irreversible EGFR inhibitor, afatinib (Fig.4C) . 
both gefitinib and afatinib while GeSB-R remained fairly sensitive to afatinib. Afatinib 1 treatment induced a small degree of apoptosis in GeSB-R cells (Suppl. Fig.4C ). 2 We extracted DNA from HCC4006, Ge-R, and GeSB-R cells and performed (Fig.5A) . DNA samples were next subjected to droplet digital PCR (ddPCR) assays 7 that have been used to detect rare mutations (30). The prevalence of EGFR T790M 8 mutation detected was highest in GeSB-R cells (18.3%) and was significantly lower in 9 Ge-R cells (1.2%) (Fig.5B) . 
Previous reports suggested that the T790M mutation pre-exists in cis with a 1 primary EGFR activating mutation in a small population and is positively selected upon T790M (18,34) . In contrast, the 4 prevalence of T790M in gefitinib-resistant HCC4006 cells (Ge-R) was fairly low (1.2%) 5 and the impact of T790M in gefitinib resistance was not evident unless HCC4006 cells 6 were co-treated with gefitinib and SB431542 (GeSB-R). Consequently, we tried to 7 estimate the prevalence of preexisting cell population with T790M both in PC9 and in 8 HCC4006. We performed ddPCR using a high number of replicates (250000 Genome 9 Equivalent (GE) in 48 wells) to evaluate the relative frequency of T790M allele 10 compared to wild-type T790 allele (Fig.6A ). We were able to identify the presence of Fig.2D ). The mesenchymal cells are resistant to EGFR TKIs and lose expression 3 of ERBB receptors while they maintain downstream pathways critical for proliferation 4 and survival (Fig.2F) . Despite the phosphorylation of EGFR and AXL that was 5 demonstrated on RTK arrays, mesenchymal Ge-R cells did not appear to depend on was only evident in parental HCC4006 cells, not in GeSB-R (Suppl. Fig.5A ). This result 10 suggests the presence of a heterogeneous population in GeSB-R cells and also 11 suggests that the utility of third-generation mutant-selective EGFR TKIs that inhibit 12 T790M might be attenuated in cells comprised of a heterogeneous population.
Whether the resistance mechanisms to EGFR TKIs evolve under the selective 14 pressure of the drugs or pre-exist prior to treatment is the subject of ongoing 15 investigation. Here, we performed ddPCR-based T790M detection in HCC4006 cells 16 and in PC9 cells and found a small subpopulation of the cells harboring T790M mutant 17 allele in both cell lines with frequencies of 0.0738% and 0.0360%, respectively. (Fig.6B) . necessarily predict the emergence of EGFR TKI resistance with T790M. The fact that 1 the frequency of T790M alleles in HCC4006Ge-R (Fig.5B, 1.2% ) was much lower than 2 the frequency in HCC4006GeSB-R suggests that heterogeneous tumors inherently 3 possess the potential to give rise to EGFR TKI resistant cells with different resistance 4 mechanisms depending on the treatment (Fig.6C) . Our results from STR analysis also 5 support the notion that the cells with a discrete genetic makeup are selected by a 6 particular treatment regimen from the heterogeneous cell population. Taken together, 7 our results highlight the difficulty in interpreting results from functional assays that utilize 8 human NSCLC cell lines harboring EGFR mutation, since we need to account for tumor 9 heterogeneity within the cell population. (Fig.1F) . In contrast, HCC4006 17 cells reproducibly develop EMT-associated EGFR TKI resistance (Fig.1B) (14) . 18 In HCC4006 cells concurrently treated with gefitinib and SB431542, the 19 mesenchymal marker vimentin, initially increased then decreased (Fig.4B ). This 
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